|REACTIVITY||H M R|
|MW (kDa)||42, 45|
For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
NOTE: Please refer to primary antibody product webpage for recommended antibody dilution.
NOTE: Prepare solutions with reverse osmosis deionized (RODI) or equivalent grade water.
Load 20 µl onto SDS-PAGE gel (10 cm x 10 cm).
NOTE: Volumes are for 10 cm x 10 cm (100 cm2) of membrane; for different sized membranes, adjust volumes accordingly.
* Avoid repeated exposure to skin.
posted June 2005
revised June 2020
Protocol Id: 263
Human, Mouse, Rat
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human GNAS/Gαs protein.
G protein-coupled receptors (GPCRs) transmit extracellular signals through heterotrimeric G proteins (guanine nucleotide-binding proteins) (1). G proteins have three main subunits: Gα, Gβ, and Gγ. In the quiescent state, the GDP bound Gα is associated with Gβγ. Binding of ligands to GPCR causes the exchange of GDP for GTP on Gα, leading to its dissociation from the Gβγ complex (2). The released GTP-Gα further activates downstream effectors to initiate signaling events. G-protein-mediated signaling is terminated by hydrolysis of GTP by Gα intrinsic GTP hydrolase and reassociation of Gα with Gβγ to form the inactive heterotrimer.
There are four subclasses of Gα protein, Gαs, Gαi/o, Gαq/11, and Gα12/13 (3), and each is linked to a unique signaling pathway. Gαs is encoded by the GNAS gene. This G protein subunit is associated with a wide spectrum of disorders (4). The GTP bound Gαs activates adenylyl cyclase, which catalyzes the conversion of ATP into the second messenger cAMP and initiates the downstream PKA pathway (5). Mutations on residue Arg201 or Gln227 result in loss of GTP hydrolase activity (6), leading to constitutive activation of Gαs, which contributes to tumor progression (7,8), fibrous dysplasia of bone (9), and McCune-Albright syndrome, a disorder that causes abnormal skin pigmentation, scar tissue formation on bone, and growth-regulating gland malfunction (10). Heterozygous loss-of-function mutations in Gαs lead to Albright hereditary osteodystrophy (AHO), a disease characterized by short stature, obesity, brachydactyly, subcutaneous ossification, and dental deficits (11).
Explore pathways related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.